Novartis to pay up to $1.6B for immunology firm subsidiary

Alia Paavola - Print  | 

Novartis has agreed to acquire a subsidiary of IFM Therapeutics for a potential total of nearly $1.6 billion, including $310 million up front, and up to $1.27 billion in milestone payments, according to Reuters.

Under the deal, IFM will sell off IFM Tre and its assets, which focus on immune system drugs. IFM Tre has one drug, IFM-2427, in an early phase 1 trial and two other less-developed assets.

In buying three potential drugs, Novartis hopes to expand its pipeline of treatments for  inflammatory disorders.

The deal is scheduled to close in the second quarter of this year.

More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy's legal win expected to lower cost of opioid addiction treatment

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.